Beta-Adrenergic Blocking Drugs

Mechanism of Action

  • Selective Beta Blockers (β1 only)
    • Act mainly on β1 receptors in the heart.
    • Reduce heart rate, contractility, and cardiac output.
    • Preferred in patients with asthma or COPD since they avoid blocking β2 receptors in the lungs.
  • Non-Selective Beta Blockers (β1 + β2)
    • Block both β1 receptors in the heart and β2 receptors in lungs and blood vessels.
    • Reduce heart rate and contractility, but also cause bronchoconstriction and peripheral vasoconstriction.
    • Useful in conditions like migraine prophylaxis, portal hypertension, and thyrotoxicosis

Indications

Generally

Generated Image

Selective Beta-Blockers Non-Selective Beta-Blockers
Generated Image Generated Image

Table 1: Health Canada–Approved

Drug

Hypertension, Mild to Moderate

Hypertensive Crisis, Emergency Treatment

Heart Failure

Angina Pectoris

Acute Myocardial Infarction

Post-myocardial Infarction

Perioperative Hypertension

Supraventricular Arrhythmias

Ventricular Arrhythmias

Migraine Prophylaxis

Hypertrophic Subaortic Stenosis

Pheochromocytoma

Acebutolol

Yes

—

—

Yes

—

—

—

—

—

—

—

—

Atenolol

Yes

—

—

Yes

—

—

—

—

—

—

—

—

Bisoprolol

Yes

—

—

—

—

—

—

—

—

—

—

—

Carvedilol

—

—

Yes

—

—

—

—

—

—

—

—

—

Esmolol

—

—

—

—

—

—

Yes[a]

Yes

—

—

—

—

Labetalol

Yes (oral)

Yes (IV)

—

—

—

—

—

—

—

—

—

—

Metoprolol

Yes

—

—

Yes

Yes (IV)

Yes (oral)

—

—

—

—

—

—

Nadolol

Yes

—

—

Yes

—

—

—

—

—

—

—

—

Nebivolol

Yes

—

—

—

—

—

—

—

—

—

—

—

Pindolol

Yes

—

—

Yes

—

—

—

—

—

—

—

—

Propranolol

Yes

—

—

Yes

—

Yes (oral)

—

Yes

Yes

Yes

Yes

Yes

Sotalol

—

—

—

—

—

—

—

—

Yes

—

—

—

Timolol

Yes

—

—

Yes

—

Yes

—

—

—

Yes

—

—

Selective vs Non-Selective β-Adrenergic Blockers 

Feature Selective β-Blockers (β1-Selective) Non-Selective β-Blockers (β1 + β2)
Primary receptor activity β1 > β2 (cardioselective) β1 + β2 (no selectivity)
Examples (common) Metoprolol, Atenolol, Bisoprolol, Nebivolol, Esmolol Propranolol, Nadolol, Timolol, Sotalol
Mechanism (key effects) ↓ HR, ↓ contractility, ↓ AV conduction, ↓ renin release Same β1 effects plus β2 blockade → ↓ bronchodilation, ↓ glycogenolysis
Effect on lungs Minimal at low–moderate doses Bronchoconstriction risk
Effect on glucose metabolism Less interference with hypoglycemia awareness Masks hypoglycemia; ↓ glycogenolysis
Effect on peripheral vasculature Neutral or mild vasodilation (nebivolol → NO release) May worsen peripheral vasoconstriction
Intrinsic sympathomimetic activity (ISA) Rare (acebutolol – less used) Possible (pindolol – uncommon)
CNS penetration Variable (metoprolol moderate) High with lipophilic agents (propranolol)
Renal elimination Atenolol (renal) Nadolol (renal)
Hepatic metabolism Metoprolol, nebivolol Propranolol
Heart failure (HFrEF) Preferred (metoprolol succinate, bisoprolol) Generally avoided (except carvedilol – mixed α/β)
Hypertension First-line when compelling indication Not preferred unless specific indication
Arrhythmias Rate control in AF, SVT Sotalol for ventricular arrhythmias (QT risk)
Ischemic heart disease Strong evidence Effective but more adverse effects
Migraine prophylaxis Less effective Preferred (propranolol, timolol)
Portal hypertension / variceal bleed Ineffective Drug of choice (propranolol, nadolol)
Thyrotoxicosis Limited Preferred (propranolol inhibits T4→T3)
Essential tremor Limited Preferred (propranolol)
Glaucoma (topical) Not used Timolol ophthalmic
COPD / asthma Preferred if needed Contraindicated
Diabetes mellitus Preferred Use caution
Pregnancy Metoprolol preferred Propranolol acceptable (monitor fetal growth)

Key Clinical Pearls (High-Yield) Selective β-Blockers

  • Lose selectivity at high doses → β2 blockade possible
  • Metoprolol succinate ≠ tartrate (HF vs acute use)
  • Nebivolol: NO-mediated vasodilation → better metabolic profile
  • Esmolol: ultra-short acting → ICU/OR rate control

Non-Selective β-Blockers

  • Avoid in asthma, severe COPD, PAD
  • Mask adrenergic symptoms of hypoglycemia
  • Propranolol useful for CNS indications due to lipophilicity
  • Sotalol = β-blocker + class III antiarrhythmic (QT monitoring mandatory)

Practice-Oriented Selection Guide

 

Patient Scenario Preferred Class
HFrEF β1-selective
COPD/asthma β1-selective
Diabetes with hypoglycemia risk β1-selective
Migraine, essential tremor Non-selective
Portal hypertension Non-selective
Thyroid storm Non-selective
ICU tachyarrhythmia β1-selective (esmolol)

Monitoring Parameters (Both Classes)

  • HR, BP
  • ECG (PR interval, QT for sotalol)
  • Signs of HF decompensation
  • Blood glucose (diabetics)
  • Respiratory symptoms (non-selective)

β-Blockers: Renal & Hepatic Dose Adjustment (High-Yield)

Drug Selectivity Elimination Renal Adjustment Hepatic Adjustment Key Pharmacist Pearl
Metoprolol β1 Hepatic (CYP2D6) ❌ ✔️ Start low Genetic variability → exposure ↑
Atenolol β1 Renal ✔️ Required ❌ Accumulates in CKD
Bisoprolol β1 Renal + hepatic ✔️ (severe CKD) ✔️ Balanced clearance
Nebivolol β1 + NO Hepatic (CYP2D6) ❌ ✔️ Favorable metabolic profile
Esmolol (IV) β1 Esterases ❌ ❌ t½ ≈ 9 min
Propranolol Non-selective Hepatic ❌ ✔️ High first-pass metabolism
Nadolol Non-selective Renal ✔️ Required ❌ Very long t½
Sotalol Non-selective + class III Renal ✔️ Mandatory ❌ QT monitoring critical
Timolol Non-selective Hepatic ❌ ✔️ Systemic effects even topical

Mixed α/β-Blockers (Often Confused Category)

Drug β Activity α1 Blockade Common Uses Key Safety Notes
Carvedilol β1/β2 ✔️ HFrEF, HTN, post-MI Avoid severe asthma
Labetalol β1/β2 ✔️ Pregnancy HTN, hypertensive emergency Orthostasis
Bucindolol β1/β2 ✔️ (Not commonly used) Pharmacogenomic issues

Pearl: Mixed blockers reduce afterload → useful in HF & hypertensive crises, but not β1-selective.

ICU-Focused β-Blocker Selection

ICU Scenario Preferred Agent Rationale
AF with RVR (unstable) Esmolol IV Rapid titration, short t½
Post-cardiac surgery tachycardia Esmolol / Metoprolol IV Predictable control
Septic shock with tachycardia Esmolol (specialist use) ↓ HR without ↓ MAP
VT / refractory arrhythmia Sotalol / Propranolol Antiarrhythmic properties
Hypertensive emergency (pregnancy) Labetalol IV Safe, dual action
Thyroid storm Propranolol IV/PO ↓ T4 → T3 conversion

Adult vs Pediatric Dosing (Clinical Snapshot)

Drug Adult Dose (Typical) Pediatric Dose Key Notes
Metoprolol 25–200 mg/day PO 1–2 mg/kg/day HF: succinate only
Atenolol 25–100 mg/day 0.5–1 mg/kg/day Renal dosing critical
Propranolol 40–160 mg/day 1–4 mg/kg/day Infantile hemangioma
Nadolol 40–120 mg/day 0.5–1 mg/kg/day Long t½
Sotalol 80–320 mg/day Weight/BSA based QTc mandatory
Esmolol (IV) Infusion 50–300 mcg/kg/min Same ICU only

Rapid Clinical Decision Guide

Patient Factor Best Choice
CKD Metoprolol, carvedilol
Asthma/COPD β1-selective only
HFrEF Metoprolol succinate, bisoprolol, carvedilol
Diabetes β1-selective
Migraine / tremor Propranolol
Pregnancy Labetalol, metoprolol
Need rapid on/off Esmolol

β-Blockers: Clinically Relevant Drug–Drug Interactions

Interacting Drug/Class β-Blocker(s) Affected Clinical Impact Pharmacist Action
Verapamil / Diltiazem All (esp. metoprolol, propranolol) Severe bradycardia, AV block Avoid combo IV; monitor closely PO
Amiodarone Metoprolol, propranolol Bradycardia, ↑ β-blocker levels Dose reduction
Digoxin All Additive AV node suppression Monitor HR, digoxin level
CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion) Metoprolol, nebivolol ↑ exposure → bradycardia Consider dose ↓ or alternative
Insulin / sulfonylureas Non-selective > selective Mask hypoglycemia Prefer β1-selective
Clonidine (withdrawal) All Rebound HTN Stop β-blocker first
NSAIDs All ↓ antihypertensive effect BP monitoring
QT-prolonging drugs Sotalol Torsades risk Avoid or ECG monitoring

QT-Risk Stratification – Sotalol (High-Alert Drug)

Parameter Threshold Pharmacist Recommendation
Baseline QTc >450 ms (M), >470 ms (F) Avoid initiation
QTc on therapy ≥500 ms Discontinue
CrCl <60 mL/min Extend dosing interval
Electrolytes K⁺ <4, Mg²⁺ <2 Correct before dosing
Initiation — Inpatient ECG x ≥3 days
Drug interactions Macrolides, fluoroquinolones Avoid

Pearl: Sotalol = β-blocker + class III antiarrhythmic → treat as an antiarrhythmic, not just a β-blocker.

β-Blockers with Intrinsic Sympathomimetic Activity (ISA)

Drug ISA Clinical Implication Why Rarely Used
Pindolol ✔️ Less bradycardia ↓ CV protection
Acebutolol ✔️ Partial agonist Limited HF benefit
Carteolol ✔️ Less HR suppression Not guideline-preferred

Clinical Pearl:

ISA agents do NOT reduce mortality post-MI or in HF → generally avoided.

One-Page β-Blocker Selection Algorithm (Clinical Use)

Step 1 – Is there a compelling indication?

  • HFrEF → Metoprolol succinate / Bisoprolol / Carvedilol
  • Portal HTN / Variceal bleed → Propranolol / Nadolol
  • Thyroid storm → Propranolol
  • Migraine / Tremor → Propranolol

Step 2 – Assess contraindications

  • Asthma/COPD → Avoid non-selective
  • Severe bradycardia / heart block → Avoid all
  • QT prolongation → Avoid sotalol

Step 3 – Consider organ function

  • CKD → Avoid atenolol, nadolol, sotalol
  • Liver disease → Avoid propranolol high doses

Step 4 – Need rapid titration?

  • Yes → Esmolol IV
  • No → Oral β1-selective

High-Yield Exam & Practice Pearls

  • β1 selectivity is dose-dependent
  • Carvedilol ≠ cardioselective
  • Timolol eye drops can cause systemic bradycardia
  • Abrupt withdrawal → rebound tachycardia/HTN
  • Metoprolol tartrate ≠ succinate (IR vs ER)

Master β-Blocker Comparison Table (High-Yield Clinical Reference)

Drug Selectivity α-Block ISA Lipophilicity HF Mortality Benefit Key Clinical Use
Metoprolol (succinate) β1 ❌ ❌ Moderate ✔️ HFrEF, IHD
Bisoprolol β1 ❌ ❌ Low ✔️ HFrEF
Nebivolol β1 + NO ❌ ❌ High ✔️ (elderly HF) HTN, HF
Atenolol β1 ❌ ❌ Low ❌ HTN (less favored)
Esmolol (IV) β1 ❌ ❌ Low — ICU rate control
Propranolol β1/β2 ❌ ❌ High ❌ Migraine, tremor
Nadolol β1/β2 ❌ ❌ Low ❌ Portal HTN
Timolol β1/β2 ❌ ❌ Moderate ❌ Glaucoma
Sotalol β1/β2 ❌ ❌ Low ❌ AF/VT (QT risk)
Carvedilol β1/β2 ✔️ ❌ High ✔️ HFrEF, post-MI
Labetalol β1/β2 ✔️ ❌ Moderate ❌ Pregnancy HTN
Pindolol β1/β2 ❌ ✔️ Moderate ❌ Rare use

Pharmacogenomics & Metabolism (Under-Recognized but Critical)

Gene / Pathway Affected Drugs Clinical Impact Pharmacist Action
CYP2D6 poor metabolizer Metoprolol, nebivolol, propranolol ↑ plasma levels, bradycardia Start low, consider bisoprolol
CYP2D6 ultrarapid Same Subtherapeutic effect Titrate higher or switch
Renal impairment Atenolol, nadolol, sotalol Drug accumulation Extend interval
Hepatic impairment Propranolol, carvedilol ↑ bioavailability Dose reduction

Pearl:

Unexplained bradycardia on metoprolol → think CYP2D6 inhibition (SSRIs, bupropion).

Patient Counseling Checklist (Pharmacist-Ready)

Counseling Point Key Message
Initiation Expect ↓ HR; benefit may take days–weeks
Adherence Do not stop abruptly
Dizziness Rise slowly (orthostasis)
Diabetes Hypoglycemia symptoms may be masked
Asthma/COPD Report wheeze or SOB immediately
Exercise Blunted HR response is expected
Eye drops (timolol) Press nasolacrimal duct to reduce absorption
Pregnancy Labetalol preferred
Missed dose Take ASAP unless near next dose

Monitoring & Deprescribing Guide

Routine Monitoring

  • HR (goal usually 55–70 bpm)
  • BP
  • ECG (PR interval; QT for sotalol)
  • Weight, edema (HF)
  • Glucose (diabetics)
  • Respiratory status (non-selective)

When to Consider Deprescribing

Scenario Recommendation
HR <50 bpm Reduce dose
Symptomatic hypotension Taper
HF decompensation Temporarily hold
No compelling indication Gradual withdrawal
End-of-life care Deprescribe

Taper Rule:

Reduce dose by 25–50% every 3–7 days to avoid rebound tachycardia.

Ultra-Concise Clinical Takeaways (Teaching Pearls)

  • β-blockers are not interchangeable
  • β1-selectivity is dose-dependent
  • Carvedilol is NOT cardioselective
  • Sotalol = antiarrhythmic (treat with respect)
  • Timolol eye drops can cause systemic effects
  • Mortality benefit in HF is drug-specific

Recommended Website Structure (Clinician-Friendly)

For best readability and performance, do NOT place everything in one massive table. Instead:

Page Layout (Ideal)

  1. Intro (short, clinical)
  2. Core Comparison Table (Selective vs Non-Selective)
  3. Expandable Sections (accordion or tabs):
    • Mixed α/β blockers
    • ICU & special populations
    • Drug interactions
    • Monitoring & deprescribing
  4. Quick Clinical Pearls
  5. References / Guidelines

This keeps Core Web Vitals fast and avoids mobile table breakage.

Final Core Comparison Table (Website-Ready) Selective vs Non-Selective β-Adrenergic Blockers

Feature β1-Selective Blockers Non-Selective Blockers
Receptor activity β1 ≫ β2 β1 + β2
Cardiac effects ↓ HR, ↓ contractility, ↓ AV conduction Same
Pulmonary effects Minimal (dose-dependent) Bronchoconstriction risk
Glycemic effects Less masking of hypoglycemia Masks hypoglycemia symptoms
Vascular effects Neutral / mild vasodilation Peripheral vasoconstriction
CNS penetration Variable Often high
HF mortality benefit ✔️ (drug-specific) ❌ (except carvedilol*)
Preferred in COPD/asthma ✔️ ❌
Diabetes Preferred Use caution
Migraine / tremor Limited Preferred
Portal hypertension Ineffective Drug of choice
Thyroid storm Limited Preferred
Examples Metoprolol, Bisoprolol, Atenolol, Nebivolol, Esmolol Propranolol, Nadolol, Timolol, Sotalol
*Carvedilol is non-selective with α1-blockade, discussed separately.
Supporting Tables (Expandable Sections) A. Mixed α/β-Blockers
Drug β-Blockade α1-Blockade Main Uses Key Notes
Carvedilol β1/β2 ✔️ HFrEF, post-MI Mortality benefit
Labetalol β1/β2 ✔️ Pregnancy HTN, emergencies Orthostasis

B. ICU & Acute Care Selection

Scenario Preferred Agent Reason
AF with RVR Esmolol IV Rapid titration
Thyroid storm Propranolol ↓ T4→T3
Pregnancy HTN Labetalol IV Safety
Septic tachycardia Esmolol (specialist use) HR control

C. High-Risk Drug Interactions (Clinical Table)

Combination Risk Recommendation
β-blocker + verapamil/diltiazem Heart block Avoid IV
Metoprolol + CYP2D6 inhibitors Bradycardia Dose reduce
Sotalol + QT-prolonging drugs Torsades Avoid

Monitoring & Deprescribing (Very Valuable for Clinicians) Monitoring Parameters

  • HR (target often 55–70 bpm)
  • BP
  • ECG (PR, QT for sotalol)
  • Respiratory symptoms
  • Blood glucose (diabetics)

Deprescribing Rule (Boxed Tip) Taper gradually: reduce dose by 25–50% every 3–7 days to avoid rebound tachycardia and hypertension.

 
SEO Optimization (Important) Keywords to Target
  • selective vs non selective beta blockers
  • beta blocker comparison table
  • beta blockers clinical pharmacology
  • beta blockers heart failure comparison
  • beta blockers asthma diabetes safety

On-Page Tips

  • Use H2 headings for each table section
  • Add sticky table headers
  • Enable horizontal scroll on mobile only
  • Avoid column-count CSS on table pages (you already identified this issue correctly)

Internal Linking Suggestions Link this page to:

  • Heart failure medications
  • Antihypertensive drug classes
  • Antiarrhythmics (Class II)
  • ICU cardiovascular drugs
  • Drug–drug interaction tables

This significantly improves topical authority.

MASTER β-BLOCKER COMPARISON TABLE

Selective vs Non-Selective β-Adrenergic Blockers (Clinical Pharmacist Reference)

Category β1-Selective Blockers Non-Selective Blockers (β1 + β2) Clinical Pharmacist Notes
Receptor activity β1 ≫ β2 β1 + β2 Selectivity is dose-dependent
Primary cardiac effects ↓ HR, ↓ contractility, ↓ AV conduction Same Class II antiarrhythmics
Pulmonary effects Minimal at low–moderate doses Bronchoconstriction Avoid non-selective in asthma
Peripheral vascular effects Neutral / mild vasodilation Vasoconstriction Worsens PAD
Glycemic effects Less masking of hypoglycemia Masks adrenergic symptoms Prefer β1 in diabetes
CNS penetration Variable Often high (lipophilic) Propranolol → CNS effects
Heart failure (HFrEF) ✔️ Preferred ❌ (except carvedilol*) Drug-specific mortality benefit
Hypertension With compelling indication Not preferred Atenolol less favored
Arrhythmias AF, SVT rate control VT, AF (sotalol) Sotalol = QT risk
Migraine prophylaxis Limited ✔️ Preferred Propranolol
Essential tremor Limited ✔️ Preferred Propranolol
Portal hypertension Ineffective ✔️ Drug of choice Propranolol, Nadolol
Thyroid storm Limited ✔️ Preferred ↓ T4 → T3
Glaucoma (topical) Not used ✔️ Timolol Systemic absorption possible
COPD / asthma ✔️ Use if needed ❌ Contraindicated Even eye drops matter
Diabetes ✔️ Preferred ⚠️ Use caution Masks hypoglycemia
Pregnancy Metoprolol acceptable Labetalol preferred Monitor fetal growth
Renal elimination Atenolol Nadolol, Sotalol Dose adjust in CKD
Hepatic metabolism Metoprolol, Nebivolol Propranolol, Carvedilol CYP2D6 variability
Intrinsic sympathomimetic activity (ISA) Rare Possible Avoid (↓ CV protection)
ICU use Esmolol IV Labetalol IV Rapid titration
QT prolongation risk No ✔️ Sotalol Inpatient initiation
Withdrawal risk ✔️ Rebound HTN ✔️ Rebound HTN Always taper
Common examples Metoprolol, Bisoprolol, Atenolol, Nebivolol, Esmolol Propranolol, Nadolol, Timolol, Sotalol —

* Carvedilol = non-selective β-blocker with α1-blockade (HF mortality benefit)

INCLUDED MIXED α/β-BLOCKERS (Within Same Table Logic)

Drug β α1 Key Indications Key Warnings
Carvedilol β1/β2 ✔️ HFrEF, post-MI Not cardioselective
Labetalol β1/β2 ✔️ Pregnancy HTN, emergencies Orthostasis

HIGH-YIELD INTERACTIONS (Same Table Page)

Combination Risk Pharmacist Action
β-blocker + verapamil/diltiazem AV block Avoid IV
Metoprolol + CYP2D6 inhibitors Bradycardia Dose ↓
Sotalol + QT-prolonging drugs Torsades Avoid
β-blocker + clonidine withdrawal Rebound HTN Stop β-blocker first
Tags: